Sharing-our-perspective




Sharing perspectives leads to greater understanding and fuels innovation. The ​Optum Insights ​blog is where we share our perspective and challenge preconceptions to clear a new path forward


  • Register for 2019 Continuing Education

    by
    • Optum Workers' Comp
    | Jan 25, 2019
    Tag Icon
    Government Affairs, Webinar - Workers' Compensation, workers compensation, Settlement, Pharmacy, Pain Management, Clinical, Continuing Education
    From the state house, to the pharmacy, to claim resolution, Optum is kicking off its 2019 continuing education calendar with "What to watch for in 2019." See our full year of topics & register to gain the knowledge you need to move move forward this year!


  • FDA creates faster way to access over-the-counter naloxone products to treat opioid overdoses

    by
    • Optum for Workers' Compensation
    | Jan 24, 2019
    Tag Icon
    Opioids, FDA, Clinical
    The U.S. Food and Drug Administration (FDA) recently established a more rapid path for pharmaceutical companies to add over-the-counter (OTC) naloxone products to the market to increase access to naloxone – a life-saving medication used for the emergency treatment of opioid-related overdose – and help reduce opioid-related overdose deaths.


  • Missouri enacts opioid prescribing limits

    by
    • Optum
    | Aug 09, 2018
    Tag Icon
    Workers' Compensation, Pain Management, Opioids, Government Affairs
    The Missouri Legislature, in the waning hours of its session, passed legislation containing numerous changes to existing laws governing medical and pharmacy practices. One tucked away segment of the bill imposes prescribing restrictions for initial prescriptions of opioids to treat acute pain.


  • Tennessee enacts enhanced opioid prescribing controls

    by
    • Optum Workers' Comp
    | Jun 01, 2018
    Tag Icon
    Opioids
    House Bill 1831 was recently signed by Tennessee’s Governor, which enacts prescribing restrictions on opioid analgesics; sets dose caps on morphine milligram equivalent (MME); and defines enhanced prescription drug monitoring program (PDMP) requirements. Effective July 1, 2018, the bill bases prescribing restrictions on various treatment timeframes and requires the prescriber to properly examine, justify and document the need for additional opioid treatment.


  • Opioid analgesics have a place in therapy; knowing when and how to use is key

    by
    • Optum Workers' Comp
    | Jul 11, 2017
    Tag Icon
    Workers Comp, Pain Management, Opioids, FDA, Chronic Pain
    The recent agreement between the U.S. Food and Drug Administration (FDA) and Endo Pharmaceuticals to have Opana® ER removed from the U.S. market highlights the ongoing need for awareness on the safety of opioid analgesics and a better understanding of how the medication can affect the major body systems. While this decision resulted from research determining the benefits of using reformulated Opana ER no longer outweigh its risks, the question of whether or not opioid analgesics should continue to have a place in medication therapy remains.



Stay informed by receiving latest updates

Do you have a question about a blog post?